Epigenetic Glaucoma Therapy Shows Early Safety, Vision Signals

The first human test of a therapy designed to reverse aging inside the eye has produced its first results. Life Biosciences announced on October 8 that ER-100, its experimental epigenetic glaucoma therapy built on partial cellular reprogramming, was well tolerated through day 56 in all three participants in an ongoing Phase 1 trial, according to the company's announcement. Two of the three participants also showed preliminary signals of improvement in visual field testing. The trial's data safety monitoring board recommended escalating to dose level two. The results, reported by BioSpace, are the first readout in people for a treatment that targets the aging of the cells themselves.

How the epigenetic glaucoma therapy works

The epigenetic glaucoma therapy delivers three genes, OCT4, SOX2 and KLF4, into retinal cells with an adeno-associated virus vector. The genes make up the OSK set known from reprogramming research, and the design deliberately omits a fourth factor, c-Myc, which is the one most linked to tumor risk. A daily oral dose of doxycycline, an ordinary antibiotic, switches the genes on for a short, controlled window. The point is to partially reset the epigenetic marks that tell aging cells which genes to use, without pushing them back so far that they forget their identity as retinal cells. In mice, this kind of brief reset restored function in damaged retinal tissue. The current trial is the first attempt to run the same playbook in people.

Why the eye is the proving ground

The approach traces back to aging research led by Harvard geneticist David Sinclair, a co-founder of Life Biosciences. His laboratory reported in 2020 that the OSK factors could restore vision in mice with injured optic nerves, with damaged retinal cells regaining function after the epigenetic reset. Federal regulators cleared the first human trial in January, and the first participant received the one-time intravitreal injection in June, according to earlier reporting by MedicalDaily. That made the trial the first regulated test of partial epigenetic reprogramming in people. The company plans to study the treatment in NAION as well, a sudden form of vision loss sometimes called eye stroke.

Glaucoma has never had a treatment that restores sight

Glaucoma damages the retinal ganglion cells that carry visual signals from the eye to the brain. About 3 million Americans live with the disease, and once those nerve cells are injured, the vision loss is considered permanent. Existing drugs can only lower pressure inside the eye to slow the damage; no approved treatment restores sight that has already been lost. That is why the eye makes sense as the proving ground for this epigenetic glaucoma therapy. A single injection reaches the target tissue directly, visual field tests can measure function with unusual precision, and the unmet need is clear. If rejuvenating old cells works anywhere, the company argues, the evidence should show up here first.

Safety first, efficacy later

The headline from this readout is safety, not efficacy. Early-stage trials are designed to establish that a new treatment can be given without unacceptable harm, and on that measure the announcement is encouraging: no dose-limiting toxicities, no adverse events of special interest and no serious adverse events were reported. The visual field improvements in two participants are described as preliminary signals, not proof that lost vision returned. With only three people treated, much larger studies will be needed to tell whether the approach genuinely reverses optic nerve damage. The next step is dose level two, which the independent monitoring board has now endorsed.

The company's chief scientific officer, Sharon Rosenzweig-Lipson, said the findings provide early information on tolerability and that the team was encouraged by the board's decision to escalate dosing. She called the milestone an important step in turning epigenetic restoration into a new class of medicines for age-related diseases, in a statement accompanying the announcement. Independent researchers will want peer-reviewed data and longer follow-up on the epigenetic glaucoma therapy before concluding anything about whether partial reprogramming works in people. For now, the trial has shown that partial reprogramming can at least be tested safely in the human eye, and the next dose will tell whether it can do more.